This will aid devising innovative therapeutic strategies based on the inhibition of CD39-AS to re-establish immunotolerance in Crohn’s disease as well as other chronic inflammatory conditions associated with CD39 defects. This evidence concerns the gene ENTPD1 and Crohn disease.